ARS Pharmaceuticals (SPRY) Set to Announce Quarterly Earnings on Wednesday

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) is set to post its quarterly earnings results before the market opens on Wednesday, November 13th. Analysts expect ARS Pharmaceuticals to post earnings of ($0.18) per share for the quarter. Investors that wish to listen to the company's conference call can do so using this link.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $0.50 million during the quarter, compared to the consensus estimate of $2.00 million. On average, analysts expect ARS Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ARS Pharmaceuticals Trading Up 2.7 %

ARS Pharmaceuticals stock traded up $0.42 during mid-day trading on Thursday, hitting $16.14. The stock had a trading volume of 588,007 shares, compared to its average volume of 772,529. The stock has a market capitalization of $1.56 billion, a PE ratio of -33.45 and a beta of 0.90. The stock has a 50-day simple moving average of $14.16 and a two-hundred day simple moving average of $11.38. ARS Pharmaceuticals has a 12 month low of $3.38 and a 12 month high of $17.08.

Analysts Set New Price Targets

SPRY has been the topic of several research analyst reports. Leerink Partners raised their price objective on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an "outperform" rating in a research note on Friday, September 20th. Cantor Fitzgerald reissued an "overweight" rating and set a $30.00 price target on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. William Blair raised shares of ARS Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th. Finally, Raymond James upgraded ARS Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and lifted their target price for the stock from $18.00 to $22.00 in a research note on Tuesday, August 13th. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $24.00.

Insider Transactions at ARS Pharmaceuticals

In other news, insider Sarina Tanimoto sold 100,000 shares of the firm's stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $14.88, for a total transaction of $1,488,000.00. Following the transaction, the insider now directly owns 1,298,499 shares of the company's stock, valued at approximately $19,321,665.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other ARS Pharmaceuticals news, Director Peter A. Thompson sold 407,700 shares of the business's stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $13.56, for a total transaction of $5,528,412.00. Following the completion of the transaction, the director now directly owns 544,677 shares in the company, valued at $7,385,820.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Sarina Tanimoto sold 100,000 shares of the firm's stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $14.88, for a total value of $1,488,000.00. Following the completion of the sale, the insider now directly owns 1,298,499 shares in the company, valued at approximately $19,321,665.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,055,895 shares of company stock valued at $14,619,032. 40.10% of the stock is currently owned by corporate insiders.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.